Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock Price Down 1.8%

Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) dropped 1.8% during trading on Wednesday . The stock traded as low as $0.80 and last traded at $0.81. Approximately 1,251 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 9,554 shares. The stock had previously closed at $0.83.

Eloxx Pharmaceuticals Stock Performance

The firm’s 50-day moving average is $0.93 and its 200 day moving average is $1.15. The stock has a market cap of $2.54 million, a PE ratio of -0.09 and a beta of 2.75.

Hedge Funds Weigh In On Eloxx Pharmaceuticals

A hedge fund recently bought a new stake in Eloxx Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 275,000 shares of the company’s stock, valued at approximately $1,323,000. Armistice Capital LLC owned about 10.00% of Eloxx Pharmaceuticals as of its most recent filing with the SEC. 2.90% of the stock is owned by hedge funds and other institutional investors.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.